Group 1 - Alan Brochstein is a pioneer in the cannabis investment sector, having focused exclusively on this industry since 2007 [1] - He founded AB Analytical Services to provide independent consulting to registered investment advisors [1] - Brochstein is the managing partner of New Cannabis Ventures, which has been a key provider of financial information in the cannabis industry since 2015 [1] Group 2 - Alan has led the investing group 420 Investor since 2013, which focuses on publicly-traded cannabis stocks [2] - The group covers 20 stocks, providing investment news, earnings report previews, and post-report analyses [2] - Additional features of the group include a model portfolio, 10 weekly videos with chart analysis, 3 weekly summary pieces, a monthly newsletter, and a chat for questions [2]

CHICAGO and MINNEAPOLIS, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (“Vireo”) (CSE: VREO; OTCQX: VREOF) and Verano Holdings Corp. (“Verano”, Vireo and Verano, each a “Company”) (Cboe CA: VRNO) (OTCQX: VRNOF) today announced that they have reached a comprehensive settlement (the “Settlement Agreement”) dismissing all outstanding litigation matters between the two Companies that are pending before the Supreme Court of British Columbia, Canada. The terms of the Settlement Agreement were approved by th ...

Core Insights - Verano Holdings Corp. reported its financial results for Q3 2025, showing a mixed performance with revenues slightly increasing from the previous quarter but declining year-over-year due to price compression and competition [1][5][6]. Financial Performance - Revenues for Q3 2025 were $202.8 million, a decrease of 6.4% from $216.7 million in Q3 2024 but an increase from $202.3 million in Q2 2025 [2][5]. - Gross profit was $95.2 million, representing 47% of revenue, down from 50% in Q3 2024 and 56% in Q2 2025, attributed to revenue declines and increased costs [6][8]. - The company reported a net loss of $43.8 million, or 22% of revenue, compared to a net loss of $42.6 million, or 20% of revenue in Q3 2024 [8][9]. - Adjusted EBITDA for Q3 2025 was $53.1 million, or 26% of revenue, down from $64.5 million, or 30% of revenue in Q3 2024 [9][30]. Operational Highlights - The company has expanded its retail footprint, opening its 82nd dispensary in Florida and increasing its Ohio locations to six [15]. - Verano secured a $75 million revolving credit facility, drawing $50 million to retire higher interest debt [15]. - The company is planning new product innovations for the upcoming retail holiday season, aiming for a strong finish to 2025 [4][5]. Balance Sheet and Liquidity - As of September 30, 2025, Verano's current assets totaled $385 million, with cash and cash equivalents at $83 million [13]. - The company had total debt of $401 million and working capital of $242 million [13][28]. Future Outlook - Management expressed optimism about long-term growth opportunities and plans for a transformative year in 2026, supported by infrastructure investments and brand performance improvements [4][5].

Core Insights - 420 Investor, launched in 2013, has transitioned to Seeking Alpha, continuing its focus on cannabis stocks and providing extensive coverage of the sector [1] - Alan Brochstein, CFA, leads the 420 Investor group, which closely monitors 20 cannabis stocks, offering investment news, earnings report previews, and post-report analyses [1] - The group features a model portfolio, weekly video analyses, summary pieces, a monthly newsletter, and a chat function for investor inquiries [1] Company Background - Alan Brochstein has been a financial professional since 1986, initially managing investments in institutional settings before founding AB Analytical Services in 2007 [1] - He is also the managing partner of New Cannabis Ventures, which has been providing financial information relevant to the cannabis industry since 2015 [1]

Industry Overview - The cannabis industry is evolving with potential U.S. federal reform and international market expansion, leading to increased global demand for both medical and recreational cannabis [1] - Analysts project the U.S. cannabis market could exceed $50 billion by 2030, driven by growing legalization efforts and shifting consumer attitudes [1] - Navigating this sector requires careful attention to fundamentals, technical analysis, and disciplined risk management [1] Company Highlights IM Cannabis Corp. (IMCC) - IM Cannabis is an international medical cannabis company headquartered in Israel, focusing on the medical market through pharmacy networks and online distribution [3][5] - The company reported a notable increase in annual revenue in 2024, reflecting rising medical demand in Israel and Germany, with modest revenue growth and a small net profit in Q1 2025 [5][11] - IM Cannabis represents a stable, lower-risk option for investors seeking medical cannabis exposure with a strong international foundation [5] Cronos Group Inc. (CRON) - Cronos Group is a Canadian cannabinoid company with a global strategy, focusing on both recreational and medical markets [6][8] - The company reported solid year-over-year revenue growth, supported by strong Canadian adult-use sales and expanding global demand, with improved gross profit margins [8] - Cronos maintains one of the strongest balance sheets in the cannabis industry, providing flexibility for future acquisitions or U.S. market entry [8][11] Aurora Cannabis Inc. (ACB) - Aurora Cannabis is one of Canada's largest cannabis producers, serving both recreational and medical markets with a wide international footprint [9][10] - The company reported significant revenue growth year-over-year, driven by rising medical sales and improved distribution efficiency, with a return to consistent profitability [10][11] - Aurora remains one of the few large-scale producers generating sustainable profits in the global cannabis space, appealing to investors looking for scale and stability [10][11]

VANCOUVER, British Columbia, Oct. 28, 2025 (GLOBE NEWSWIRE) -- LEEF Brands Inc. (CSE: LEEF) (OTCQB: LEEEF), a leading multi-state operator, today announced that it will release its financial results for the third quarter ended September 30, 2025, after market close on Tuesday, November 4, 2025. The Company will host a conference call to discuss the results at 5:00 p.m. Eastern Time on the same day. The call will be led by Micah Anderson, Chief Executive Officer, Kevin Wilson, Chief Financial Officer, and Je ...

Core Insights - Ayurcann Holdings Corp. has reported strong financial and operational results for the fiscal year ended June 30, 2025, highlighting its growth and market position in the Canadian cannabis industry [1][5]. Financial Highlights - Gross revenue reached CAD 55,446,352 for the fiscal year 2025, an increase from CAD 45,265,235 in 2024, reflecting a significant year-over-year growth [8]. - Adjusted EBITDA improved to CAD 507,570, compared to a loss of CAD 352,492 in FY2024, indicating a turnaround in financial performance [8]. Operational Highlights - The product portfolio has expanded to 80 SKUs nationwide, demonstrating the company's commitment to innovation and product diversity [8][9]. - Ayurcann's products are available in over 75% of licensed retail cannabis stores across Canada, showcasing a robust national distribution network [3]. - In Ontario, the largest cannabis market in Canada, Ayurcann has achieved over 80% retail penetration, with products in more than 1,500 licensed stores [4]. Market Position - Ayurcann has maintained a 100% year-over-year sales growth for the past three fiscal years (2021-2024), underscoring its operational strength and market leadership [2]. - The company has established strong relationships with the Ontario Cannabis Store and retail partners, enabling it to capture significant market share [4]. Corporate Update - Ayurcann will voluntarily delist from the OTCQB effective October 30, 2025, while continuing to trade on the Canadian Securities Exchange under the ticker symbol "AYUR" [10].

Core Insights - Cronos Group Inc. is reintroducing its limited-edition Caramel Green Apple flavor to its SOURZ by Spinach edibles lineup for the fall and Halloween season, following a successful launch in Fall 2024 [1][2] - The company is expanding its seasonal offerings with two new products, emphasizing the importance of limited-time products to connect with consumers during the fall [2] - Cronos is committed to advancing cannabis research, technology, and product development, aiming to build a diverse and iconic brand portfolio [3] Product Offerings - The original SOURZ by Spinach Caramel Green Apple 5-pack of gummies is being brought back, along with two new seasonal products [2] - The new products are designed to celebrate popular fall flavors, enhancing the consumer experience during this time of year [2] Company Overview - Cronos Group Inc. is described as an innovative global cannabinoid company focused on building disruptive intellectual property and advancing cannabis research [3] - The company has a diverse international brand portfolio that includes Spinach, PEACE NATURALS, and Lord Jones [3]

Core Viewpoint - Verano Holdings Corp. has received shareholder approval to redomicile from British Columbia, Canada, to Nevada, with plans to finalize the process as soon as possible despite delays due to an employee strike at the British Columbia Registrar of Companies [1][2]. Company Overview - Verano Holdings Corp. is a leading multi-state cannabis company in the U.S., recognized for its historical revenue, geographic reach, and brand performance [5]. - The company operates under various dispensary brands, including Zen Leaf and MÜV, and offers a range of high-quality cannabis products through its diverse portfolio [5]. - Verano's operations span 13 U.S. states, with 15 production facilities and over 1.1 million square feet of cultivation capacity [5]. Redomicile Details - The redomicile plan involves a Continuance from British Columbia to Nevada, where existing subordinate voting shares will be exchanged on a one-for-one basis for Nevada Common Stock [3]. - All outstanding stock options and restricted stock units will be adjusted to reflect the new Nevada Common Stock [3].

Group 1 - A new initiative by top American legal officials to limit certain cannabis products has negatively impacted the stock prices of marijuana companies, particularly Trulieve Cannabis, which saw a decline of over 4% on the day the news was released [1][2] - The S&P 500 index, in contrast, experienced a rise of 1.2% on the same day, indicating a broader market resilience despite the specific downturn in cannabis stocks [1] - A bipartisan group of 39 state and territory attorneys general expressed concerns about the federal definition of hemp and its exploitation for selling synthetic THC products, urging Congress to clarify the term and modify policies to make fake THC products illegal [2][4][6] Group 2 - The attorneys general highlighted that the legalization of hemp in 2018 has led to ambiguities in federal law, which they believe is being exploited by bad actors in the market [4][6] - If the proposed changes to federal law are successful, it could lead to increased scrutiny and higher compliance costs for hemp product manufacturers like Trulieve Cannabis [4]